Stay updated on Fostamatinib in COVID-19: Efficacy & Safety Clinical Trial
Sign up to get notified when there's something new on the Fostamatinib in COVID-19: Efficacy & Safety Clinical Trial page.

Latest updates to the Fostamatinib in COVID-19: Efficacy & Safety Clinical Trial page
- Check5 days agoChange DetectedThe study record no longer displays the 2023-08-18 date associated with “Certification/Extension First Posted.”SummaryDifference0.1%

- Check12 days agoChange DetectedThe page displays the ClinicalTrials.gov record for a completed Phase 3 study of fostamatinib for COVID-19, including its eligibility criteria, locations, interventions, and outcome measures.SummaryDifference66%

- Check19 days agoChange DetectedThe footer revision identifier changes from v3.7.2 to v3.8.0 on a page displaying a 403 Forbidden response.SummaryDifference0.2%

- Check25 days agoChange DetectedA site-wide notice announces NIH’s terminology transition from “Artificial Intelligence” to “Super Intelligence.” The clinical trial study record remains inaccessible behind a 403 error.SummaryDifference1%

- Check32 days agoChange DetectedThe footer’s site revision identifier changes from v3.7.1 to v3.7.2.SummaryDifference0.3%

- Check39 days agoChange DetectedThe site release identifier was updated from v3.7.0 to v3.7.1.SummaryDifference0.3%

Stay in the know with updates to Fostamatinib in COVID-19: Efficacy & Safety Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fostamatinib in COVID-19: Efficacy & Safety Clinical Trial page.